Podcast Summary: Dr. Chapa’s OBGYN Clinical Pearls

Episode: Vaginal GSpot Injection: Again?
Date: March 29, 2026
Host: Dr. Chapma

Episode Overview

This episode delves into the topic of the G-spot injection (aka "G-shot") and its resurfacing in popular and clinical conversations, particularly in light of a new randomized controlled trial (RCT) investigating platelet-rich plasma (PRP) injections into the anterior vaginal wall for sexual function. Dr. Chapma critically evaluates the evidence, provides historical context, and discusses the anatomical, clinical, and ethical considerations surrounding this emerging—and controversial—practice.

Key Discussion Points & Insights

1. Background of the G-Spot and the G-Shot (01:09–03:59)

G-Spot vs. G-Shot:
- The G-spot is a controversial erogenous zone in the anterior vaginal wall.
- The "G-shot" is an injection (historically collagen, now also PRP) aimed at enhancing this area to improve sexual function.
- Plastic surgeons popularized the procedure via media (notably, Dr. 90210).
Clinical Skepticism:
- Many providers, including the speakers, express doubt about the scientific validity and significant placebo effects.
- "A lot of the women that I've injected, some women come in and say, oh, my God, it's the best thing that’s ever happened. I have some women that come and be like, didn’t feel much of a difference. I don’t know." (Casual Commentator, 01:28)

2. Rise of PRP Injections & New Study (03:59–11:18)

Historical Trajectory:
- PRP was originally used in hematology for thrombocytopenia, later adopted in dental/maxillofacial and orthopedic fields for tissue regeneration and healing.
Use in Gynecology:
- Off-label PRP injections have been tried for vaginal rejuvenation, lichen sclerosus, and even premature ovarian insufficiency, though it remains experimental.
Current Evidence:
- PRP for G-spot/vaginal injection is not FDA-approved for any gynecological indication.
- New RCT (Green Journal, Mar 19, 2026):
  - Title: Vaginal Injection of Platelet Rich Plasma for Sexual Function
  - Authors include leading figures in urogynecology (e.g., Barbie Garcia, Cheryl Iglesia).

"The problem is, you got to keep getting some injections because nobody knows if you just need one, if you need four, if you need five. ... Right now, you just can't order from a company your little vials of PRP. ... These are mainly all done off-label." (Dr. Chapma, 05:00–06:12)

3. Anatomical Rationale & Mechanistic Theory (09:48–11:18)

Why the Anterior Vaginal Wall?
- Homologous to sensitive male anatomy; strong sensory innervation.
- Proximity to clitoral "wishbone" structure and trigone/bladder neck area.
- Anatomically plausible as an erogenous zone but not universally so.

"The anterior vaginal wall absolutely is considered an erogenous zone. So the idea of anything that can plump that area up ... bring natural healing ... that’s the idea." (Dr. Chapma, 10:40)

4. RCT Review: Design, Results & Critical Appraisal (12:50–20:22)

Study Design:
- Small, pilot RCT (Single center, single-blind, N=52; 26 PRP, 26 control).
- Included women age 18–50 without severe sexual dysfunction (already baseline functional).
- Used the validated Female Sexual Function Index (FSFI) to assess outcomes.
Intervention:
- PRP or control injected into the anterior vaginal wall (approx. 3 cm from urethral meatus).
- Follow-up at 6 weeks (primary) and 6 months (secondary).
Findings:
- Both at 6 weeks and 6 months, the PRP group had a numerically greater increase in FSFI scores (desire, arousal, lubrication, orgasm) than control.
- BUT: No statistically significant difference.
- Subjective patient global impression of improvement score favored PRP, but again, clinical significance is questionable given small sample and lack of baseline dysfunction.
Adverse Events:
- No serious events; theoretical risks of urinary hesitancy or obstruction if injection technique is flawed.
Critical Perspective:
- Study not powered for commercial application; procedure remains investigational.
- Further, larger multicenter trials needed.

"Results are like, okay. I mean, they're not like, wow, this is amazing ... It opens up the discussion." (Dr. Chapma, 13:58)

"Even though ... changes were not statistically significantly different compared to control." (Dr. Chapma, quoting the paper, 15:50)

5. Context, Skepticism & Take-Home (18:00–20:22)

Cyclical Trend:
- Adds historical perspective: Dr. 90210’s collagen G-shot over a decade ago was also met with professional skepticism.
- Medical groups and professional societies remain hesitant due to lack of robust evidence and potential risks.
Ethics & Pragmatism:
- Off-label use is not precluded, but should be discussed as experimental.
- “You do you, whatever you want to do ... With an N of 26 in the treatment group, maybe need a little bit more data.” (Dr. Chapma, 19:52)
Final Note:
- Light-hearted pun: "I think we've met our function here. Get it? Our function. We were talking about sexual function." (Dr. Chapma, 20:20)

Notable Quotes & Memorable Moments

On the Placebo Effect and Mixed Outcomes

Casual Commentator (01:28):
“A lot of the women that I've injected, some women come in and say, ‘oh, my God, it's the best thing that's ever happened.’ I have some women that come and be like, ‘didn't feel much of a difference. I don't know.’”

On PRP Use and Regulation

Dr. Chapma (06:12):
“These are mainly all done off label, but they seem to work in certain dental surgeries. ... The difficulty, because this is all autologous ... is that it has to be unified and standardized. And right now you just can't order from a company your little vials of PRP.”

On Anatomical Plausibility and the G-spot

Dr. Chapma (10:40):
“The anterior vaginal wall absolutely is considered an erogenous zone. So the idea of anything that can plump that area up ... bring natural healing to this with platelet rich plasma, that's the idea.”

On the Study’s Statistical Significance

Dr. Chapma (15:50):
“Quote: ‘Although these changes were not statistically significantly different compared to control, end quote.’ ... Statistical significance is just math, and it could be because this was only 26 patients.”

On the Ongoing Nature of the Controversy

Dr. Chapma (19:52):
“You do you, whatever you want to do. I'm just saying with an N of 26 in the treatment group, maybe need a little bit more data because the FSFI overall showed no statistical differences in their subgroups. But you know, it's interesting.”

Important Segment Timestamps

| Timestamp | Segment Description | |-----------|--------------------| | 01:09–03:59 | Introduction to G-spot and G-shot, skepticism, historical background (Dr. 90210) | | 04:00–06:12 | Platelet-rich plasma origins, historical evolution, and off-label use | | 09:48–11:18 | Anatomical discussion: anterior vaginal wall, erogenous zones, and clitoral anatomy | | 12:50–20:22 | RCT design, results, appraisal, and broader clinical/ethical considerations | | 15:50 | Discussion of (lack of) statistical significance in the new study results | | 19:52 | Final thoughts on the need for more robust data and responsible off-label use |

Summary Takeaway

Dr. Chapa’s episode provides an evidence-based, balanced, and slightly irreverent look at the reemergence of G-spot injections for sexual function, in particular the recent exploration of PRP as an “amplifier” for the controversial erogenous zone. The verdict: Interesting for “water cooler discussion,” but with no statistically significant clinical benefit demonstrated and ongoing concerns over standardization, regulation, and scientific rigor, the procedure remains in the experimental domain. Medical providers are urged to use caution, transparency, and up-to-date research before considering or advising these interventions.

Transcript

Celsius Energy Advertiser (0:00)

5:00am I'm up with a crisp Celsius energy drink running 12 miles today. Grab a green juice, quick change, and head to work. Meetings, workshops. One more Celsius. No slowing down. Working late, but obviously still meeting the girls for a little dancing. Celsius live fit. Go grab a cold, refreshing Celsius at your local retailer or locate now@celsius.com.

Casual Commentator (0:24)

so good, so good, so good.

Nordstrom Rack Advertiser (0:27)

New spring arrivals are at Nordstrom rack stores now. Get ready to save. Give big was up to 60% off. Rag and bone, Marc Jacobs, free people and more.

Casual Commentator (0:36)

How did I not know rack has Adidas?

Dr. Chapma (0:38)

Cause there's always something new.

Nordstrom Rack Advertiser (0:40)

Join the Nordy Club to unlock exclusive discounts. Shop new arrivals first and more. Plus, buy online and pick up at your favorite rack store for free. Great brands, great prices. That's why you rack.

Medical Expert (1:09)

Whether or not you're a believer, we've all heard of the G spot. The question is, have you heard of the G shot?

Dr. Chapma (1:17)

What is it?

Medical Expert (1:18)

Well, it's sort of like, you know, fillers, plumping up the cheeks. Well, you can imagine that's what's happening in a different part of the anatomy.

Casual Commentator (1:28)

We do not personally offer the G shot because it is our understanding and it is clinically proven that the G spot is a very shady area. I really think there is something where there probably is a large placebo effect to this. A lot of the women that I've injected, some women come in and say, oh, my God, it's the best thing that's ever happened. I have some women that come and be like, didn't feel much of a difference. I don't know.

Dr. Chapma (1:49)

All right, so this is a clip that's available online. It's called the G shot for the G spot. Now, okay, I gotta watch this line very carefully here because this idea is nothing new. If y' all remember from a while back, like, over a decade ago, there was a TV show that actually introduced this to the masses. It was Dr. 90210, not a sponsor. So on that show, a plastic surgeon would kind of endorse and propagate this idea of G spot amplification. This physician would inject collagen into the anterior vaginal wall about 3 cm from the urethral meatus or from the vaginal cervical reflection. The point is kind of in that middle part of the anterior vaginal wall. Ish area. Okay. And this became very popular, even though the science was a little unclear and there was no published guidance for this. All right, so this goes back to some time now, that clip that we just shared is by a plastic surgeon. So I have no issues with, you know, if it's people who do a lot of cross territories in terms of our care. But I'd feel more comfortable if this was maybe a urogynecologist, obviously if it was a, a gynecologist, a urologist even, but this was a plastic surgeon. Now why do plastic surgeons like on Dr. 90210, why are they the ones this. Well, it's very easy. They're used to injecting things in areas like fillers. All right, so this is exactly where this comes from. So this is nothing new. What is new is that we're still talking about it because in the middle of March, 2026, there's a brand new publication. It's actually an RCT, though it's a very small number. It's an RCT that looks at this very issue of G spot injection. Okay. Though they don't call it the G spot, they steer clear of that whole controversy. So there is a brand new publication that comes out of different sites, the authors out of different locations in the Green Journal, okay, the title is Vaginal Injection of Platelet Rich Plasma for Sexual Function. Vaginal Injection of Platelet Rich Plasma or PRP for Sexual Function. And it's got some big people in this. I mean, Barbie Garcia is in this. Cheryl Iglesia, who's a pillar in kind of vaginal surgery. So it's got big names to this. I don't know where this is going to go. Okay, so we've been on the road of platelet rich plasma PRP for some time and we have episodes that talk about that. And there's things that it shows promise for and things that it's just kind of the wild, wild West. Now, to be clear, Platelet rich plasma, as of right now, there is no formal and FDA approved indication to use these things. These are mainly all done off label, but they seem to work in certain dental surgeries. That's the thing. It's been a thing for a long time in certain musculoskeletal conditions like lateral epicondylitis, plantar fasciitis. This thing seems to have some data. Even in osteoarthritis, it seems to work. The problem is you got to keep getting some injections because nobody knows if you just need one, if you need four, if you need five. And the difficulty, because this is all autologous, right? They draw it from your blood, they spin it and they get Platelet rich plasma is that it has to be unified and standardized. And right now you just can't order from a company your little vials of prp. I guess you can kind of bootleg it, but there's no formal FDA approval for specific clinical conditions. Okay, same thing. In gynecology. There is data where this has shown some work in quote unquote vaginal rejuvenation. I said it. I know it's controversial and you know, I'm just going to leave it as that. Also in some vulvar dermatoses, this has shown some promise like for lichen sclerosis and it's shown some promise with premature ovarian insufficiency for patients especially who are trying to get a window of time for conception. Injected into the ovary, platelet rich plasma has shown some. Not great, but it has shown some, some promise. However, injecting anything into the ovary, even a little bit of saline because of the regenerative. The regenerative and the healing properties of the ovary, that has seemed to help as well. So it's very unclear. Okay, My point is platelet rich plasma PRP as a vaginal G spot injection is now back in press. So this has been over. I mean it's over a decade. Dr. 902 weno again brought thing to the masses. And so we're going to talk about this brand new Study published on March 19, 2026 by some wonderful people. Wonderful people. I don't know if this is going to go anywhere but good water cooler discussion. And if somebody comes to your office and says hey, I read in some Vogue magazine because that's so medical, the you can inject my G spot and it's going to be lights out, baby. Well, let's talk about it. We'll be right back. This is Dr. Chapma's OBGYN no Spin podcast. All right, so first off the bat, I do respect these authors, good for them thinking outside the box. But it's a small rct, definitely not ready for commercialization and it's not going to be widely adopted as of right now. But you do what you want to do. And I find this interesting that the term platelet rich plasma. Think about that. Platelet rich plasma. So the idea is there's a lot of platelets in it was never meant to be taken outside of its original intention. And its original target back in the 1970s when the term platelet rich plasma was first used by hematologists in order to treat a platelet poor condition. Since it's platelet rich Plasma? Yeah, it was a treatment for thrombocytopenia. So from that in the 1970s, we jump about 20 years to the 1990s. And now we get this application outside of that, mainly in dental and maxillofacial surgery, where it was found to kind of increase angiogenesis, collagen, lay down, and kind of natural healing. So there is some history to this. The problem is that right now the football field doesn't have any end zones and it has no foul lines. Right. I mean, it's just kind of open space and there's people running amok. And so we need a lot more direction on this. Again, the big issue here is because it's autologous, who qualifies for this? How do we standardize this preparation? How do we standardize the amount of mls that are used for this? And this would require, you know, large scale clinical investigation. This is a small study. Again, it's even the author's aids a pilot. It's a single center, it's single blind, and it only included in the treatment group 26 patients. 26. Now, there was a control of the same number. So 26 times two is your total RCT volume. All right, so it was 52 participants. 26 had autologous platelet rich plasma and 26 had control. Now, these were all injected into the anterior vaginal wall about 3 cm or so from the urethra meatus in that anterior wall space. Now, let's just talk about that as basic anatomy for a bit. Yes, that is the kind of controversial G spot location, although it makes a lot of sense anat it makes a lot of sense in homology, in the homologous parts of the male. That is a very sensitive area, the anterior vaginal wall, especially with continual, you know, kind of a stroking pressure, because it also sits around the trigone area where some patients, some women may get that kind of urge or sensation to void. And that's where you get the little squirting phenomenon which we have covered on this episode as well. Is that pee or is that an ejaculate type of fluid? I've covered that on this episode. It's been at at least two years that we covered that. So we've discussed that kind of phenomenon. Whether that's learned behavior, you train to do that, or it's a physiologic anatomical response. Okay, so the point is, anterior vaginal wall seems to be where it's at. Posterior vaginal wall, not so much. Anterior vaginal wall. Yes. Also because of the structure of the clitoris, which we now know is not just a little structure at the top of the vagina, it is a wishbone shape that includes the encapsulation of the introitus. And so anything that puts pressure on the vaginal wall could, you know, stimulate the clitorovaginal vestibular system. So the anterior vaginal wall absolutely is considered an erogenous zone. So the idea of anything that can plump that area up as Dr. 90210 did with collagen, or bring natural healing to this with platelet rich plasma, that's the idea. Okay.